Postsurgical Management of Differentiated Thyroid Cancer in China

Wei-Jun Wei; Guo-Qiang Zhang; Quan-Yong Luo

doi:10.1016/j.tem.2017.10.008

Postsurgical Management of Differentiated Thyroid Cancer in China

Trends Endocrinol Metab. 2018 Feb;29(2):71-73. doi: 10.1016/j.tem.2017.10.008. Epub 2017 Nov 14.

Authors

Wei-Jun Wei¹, Guo-Qiang Zhang², Quan-Yong Luo³

Affiliations

¹ Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China; Shanghai Jiao Tong University School of Medicine, Shanghai, China; Co-first authors contributed equally.
² Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China; Co-first authors contributed equally.
³ Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China. Electronic address: lqyn@sh163.net.

PMID: 29150318
DOI: 10.1016/j.tem.2017.10.008

Abstract

Postsurgical management of differentiated thyroid cancer in China has gained a great success in the last twenty years, but there are still gaps to be filled. Here, we briefly review the current status and also extend an outlook for future development.

Keywords: immunotherapy; molecularly targeted therapy; radioiodine; state-of-the-art; thyroid cancer; tumor models.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Adenocarcinoma, Follicular / surgery
Adenocarcinoma, Follicular / therapy*
Antineoplastic Agents / therapeutic use*
Carcinoma, Papillary / surgery
Carcinoma, Papillary / therapy*
China
Humans
Immunotherapy / methods*
Iodine Radioisotopes / therapeutic use*
MAP Kinase Kinase Kinases / antagonists & inhibitors*
Protein Kinase Inhibitors / therapeutic use*
Thyroid Cancer, Papillary
Thyroid Neoplasms / surgery
Thyroid Neoplasms / therapy*

Substances

Antineoplastic Agents
Iodine Radioisotopes
Protein Kinase Inhibitors
MAP Kinase Kinase Kinases